A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis
- Conditions
- Respiratory Tuberculosis
- Interventions
- Drug: Interferon-Gamma
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06118619
- Locations
- 🇷🇺
Tuberculosis Clinic of the Chuvash Republic, Cheboksary, Chuvash Republic, Russian Federation
🇷🇺Clinical Phthisiopulmonological Medical Center, Perm, Perm Region, Russian Federation
🇷🇺Leningrad Oblast Tuberculosis Clinic, Slantsy, Leningrad Oblast, Russian Federation
Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: Interferon-Gamma
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT05395702
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19
- Conditions
- COVID-19 Respiratory Infection
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05386446
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study of the Use of the Drug Ingaron in Patients With COVID-19
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05386459
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
- Conditions
- Chronic Prostatitis
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05378646
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Interferon-Gamma
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05359315
- Locations
- 🇷🇺
FSBI "NMIC FPI" of the Ministry of Health of Russia, Moscow, Russian Federation
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
- Conditions
- Human Papillomavirus InfectionAnogenital Warts
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05156541
- Locations
- 🇷🇺
State scientific center of a dermatovenereology and cosmetology, Moscow, Russian Federation
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
- Conditions
- Aids/Hiv ProblemHuman Immunodeficiency VirusLentivirus InfectionsHIV CoinfectionTuberculosis, PulmonaryRNA Virus Infections
- Interventions
- Drug: Interferon-Gamma
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05065905
- Locations
- 🇷🇺
Saint-Petersburg State Medical Academy n.a. I.I.Mechnikov of Ministry of Health, Saint Petersburg, Saint-Petersburg, Russian Federation
🇷🇺City Tuberculosis Hospital #2 of Saint-Petersburg, Saint Petersburg, Saint-Petersburg, Russian Federation
Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
- Conditions
- Acute Respiratory DiseaseCOVID-19 Respiratory Infection
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT05054114
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation